Digital mammo tops film for DCIS diagnosis
The largest study to date comparing film-screen and full-field digital mammography found the digital approach better for visualizing microcalcifications deemed crucial to diagnosing ductal carcinoma in situ.
The largest study to date comparing film-screen and full-field digital mammography found the digital approach better for visualizing microcalcifications deemed crucial to diagnosing ductal carcinoma in situ.
Dr. Nico Karssemeijer from Radboud University in Nijmegen, the Netherlands, and colleagues evaluated 367,600 screening exams performed over five years, 56,518 of which were digital. Breast cancer was found in 1927 women, 317 of whom underwent digital mammography enhanced with computer-aided diagnosis.
At initial screenings, digital detected cancer at a rate of 0.77% and film at a rate of 0.62%. Subsequent readings led to rates of 0.55% and 0.49%, respectively, for digital and film. Film-based screening detection of DCIS was 0.12% in initial exams and 0.08% in subsequent exams. Digital mammography DCIS detection was 0.22% in initial exams and 0.12% in subsequent exams (Radiol 2009 July 31 e-pub ahead of print).
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
